

Table SI. Exploratory multivariate Cox regression analysis for post-progression overall survival among patients experiencing recurrence or progression after PARP inhibitor therapy.

Variables	HR	95% CI	P-value
Platinum sensitivity after progression following PARP inhibitor use	0.125	0.027-0.584	0.008 ^a
Bevacizumab use after progression	0.847	0.293-2.450	0.760
FIGO stage IV (reference: Stage III)	0.332	0.062-1.784	0.199
Suboptimal cytoreduction	0.931	0.427-2.033	0.858
Neoadjuvant chemotherapy	1.638	0.490-5.478	0.423

^aSignificant association. HR, hazard ratio; FIGO, International Federation of Gynecology and Obstetrics; PARP, poly(ADP-ribose) polymerase.